Primary Outcome Measures:
- adverse events; clinical hematology, clinical chemistry, urinalysis, vital signs (blood pressure and heart rate), electrocardiogram (ECG) intervals, ECG rhythm, and ECG axis from predose values, pharmacokinetic parameters throughout the study [ Time Frame: throughout the study ]
Secondary Outcome Measures:
- pharmacokinetic parameters [ Time Frame: throughout the study ]
- Plasma AUC(0-t) and AUC(0-¥) of midazolam, with and without GSK1349572 co-administration (Day -1 and Day 10). [ Time Frame: Day -1 and Day 10 ]
- Pre-morning dose concentrations (Ct) on Day 2 through 10 to assess the achievement of steady state of GSK1349572 following repeat administration. [ Time Frame: day 2 thru day10 ]
- Day 10 AUC(0-t), Cmax, C0, Ct, and Cmin following last repeat dose administration at different doses for the assessment of dose proportionality. [ Time Frame: day 10 ]
- Single dose plasma GSK1349572 pharmacokinetic parameters: tmax, t1/2, tlag and CL/F.
ING111322: A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 Followed by A Single Dose, Randomized, 3-Period, Balanced, Crossover Study to Assess the Relative Bioavailability of Two Formulations and Food Effect on GSK1349572 in Healthy Male and Female Subjects